Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Monday: FXCM Inc (NYSE:FXCM), Regions Financial Corp (NYSE:RF), Zynga Inc (NASDAQ:ZNGA), CTI BioPharma Corp (NASDAQ:CTIC)

• FXCM Inc (NYSE:FXCM), with shares declined -6.20% is now trading at $2.42. The Stock is active as 4.54M shares changed hands versus its average volume of 5.02M shares.

• Regions Financial Corp (NYSE:RF), with shares declined -0.35% is now trading at $9.88. The Stock is active as 5.45M shares changed hands versus its average volume of 14.79M shares.

• Zynga Inc (NASDAQ:ZNGA) with shares dipped -1.16% is now trading at $2.56. The Stock is active as 4.66M shares changed hands versus its average volume of 19.38M shares.

• CTI BioPharma Corp (NASDAQ:CTIC), with shares rose 1.02% is now trading at $1.99. The Stock is active as 4.36M shares changed hands versus its average volume of 4.66M shares.

Latest NEWS regarding these Stocks are depicted underneath:

FXCM Inc. (NYSE:FXCM)

Today, Analysts at Keefe Bruyette & Woods., downgraded FXCM Inc. (FXCM), stock from “market perform” to “underperform”.

The firm said the corporation’s closing price of $2.58 is in its “midpoint of valuation range.”

Keefe Bruyette analysts noted that FXCM’s fourth quarter earnings beat was due to lower expenses, mainly with lower referring broker fees.

FXCM Inc., through its auxiliaries, provides online foreign exchange (FX) trading and related services to retail and institutional customers worldwide. It operates in two segments, Retail Trading and Institutional Trading. The corporation acts as an agent between retail customers and a collection of global banks and financial institutions by making foreign currency markets for customers trading in foreign exchange spot markets.

Regions Financial Corporation (NYSE:RF)

On March 11, Federal Reserve indicated to Regions Financial Corporation (RF), that it does not object to the corporation’s capital plan and projected capital actions for the second quarter of 2015 through the second quarter of 2016. The capital plan was presented to the Federal Reserve as part of the Comprehensive Capital Analysis and Review (CCAR).

Actions that Regions may undertake as outlined in its capital plan comprise increasing the quarterly ordinary dividend to $0.06 per share and the repurchase of up to $875 million in ordinary shares. The capital plan also provides the potential for a subsequent dividend raise starting in the second quarter of 2016, which is predictable to be considered by the Regions Board of Directors in early 2016.

Regions’ ongoing and robust capital planning process is designed to ensure the efficient use of capital while maintaining a long-term approach to capital allocation and distribution consistent with the corporation’s planned priorities. These projected capital actions are subject to approval by the Regions Board of Directors and consideration of other factors, counting general market conditions.

Regions Financial Corporation (RF), with $120 billion in assets, is a member of the S&P 500 Index and is one of the nation’s largest full-service providers of consumer and commercial banking, wealth administration, mortgage, and insurance products and services.

Zynga, Inc. (NASDAQ:ZNGA)

Last Week, Zynga, Inc. (ZNGA)’s partner, declared that the much-awaited game Dawn of Titans will be launched by 2015-end. Dawn of Titans, an action packed fantasy strategy game, is primarily designed for iPhone and iPad users. This led to a noteworthy rise in Zynga’s share price, despite the overall bearish momentum in the market.

Zynga Inc. develops, markets, and operates online social games as live services played on the Internet, social networking sites, and mobile platforms in the United States, Asia, and Europe.

CTI BioPharma Corp. (NASDAQ:CTIC)

Today, CTI BioPharma Corp. (CTIC), declared that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor presently in Phase 3 development in the PERSIST program. Dr. Rami S. Komrokji, Associate Professor of Oncologic Sciences at the University of South Florida College of Medicine and Clinical Director of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Fla., was the lead author.

Results of the Phase 2 study demonstrated that pacritinib is active in patients with myelofibrosis, resulting in spleen volume reduction, while producing substantial and prolonged improvement in disease-related symptoms without causing clinically noteworthy myelosuppression. We believe pacritinib was well tolerated, counting in patients with disease-related anemia and thrombocytopenia, with the predominant side effect being manageable gastrointestinal toxicity.

CTI BioPharma Corp., a biopharmaceutical corporation, engages in the attainment, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.